Abstract:Background: Aspirin (ASA) has been reported to have an antitumor effect but the role of ASA in the prevention and treatment of breast cancer (BC) is still controversial.This study aimed to identify clinical effectiveness of ASA in the treatment of BC and explore the antitumor target proteins of ASA that may be involved in overcoming tamoxifen resistance in estrogen receptor (ER)-positive BC cells.Materials and Methods: Randomized controlled trials (RCTs) of ASA in the treatment of BC were queried from the databases, including PubMed, Web of Science, Cochrane Library, WanFang, and Chinese National Knowledge Infrastructure.According to the quality standard recommended in the Newcastle-Ottawa Scale (NOS), the outcome indexes were analyzed by RevMan 5.3 and Stata 12.0 software.Cell culture experiments were performed to explore the effect of tamoxifen combined with ASA on the proliferation of ER-positive BC cell lines MCF-7 and MCF-7/TAM.Cell cytotoxicity was determined by the 3-(4, 5-di-2-yl)-2, 5-ditetrazolium bromide (MTT) assay.A quantitative proteomic analysis was conducted between the control and experimental groups to identify differentially expressed proteins (DEPs).Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were used for bioinformatic analysis of DEPs.The protein expression in patients of ER-positive BC was analyzed by immunochemistry (IHC).Results: Nine RCTs including 162,381 patients were selected for this study.The meta-analysis revealed that daily ASA use, as compared with its non-use, was associated with a decreased risk of BC death: relative risk (RR) = 0.83%, 95% CI [0.73, 0.94], Z = 2.89, P = 0.004 (P < 0.05).Cell culture experiments showed that tamoxifen combined with ASA can drastically inhibit the cell growth of MCF-7 and MCF-7/TAM cells more than the administration of tamoxifen alone (P < 0.05).Fifty-seven DEPs were up-regulated, while eighty-five DEPs were down-regulated in MCF-7/TAM cells after the ASA combination treatment.Several GO terms were significantly enriched, such as neutrophil degranulation, retinal metabolic process, sterol biosynthetic process, and prostaglandin metabolic process.KEGG pathway enrichment analysis also verified three associated pathways including metabolic pathways, chemical carcinogenesis-reactive oxygen species, and biosynthesis of amino acids.In ER-positive BC patients with Ki67 > 20%, the positive expression of one significantly DEP MYC was much higher than in BC patients with Ki67 ≤ 20% (40.91% vs. 12.50%, P < 0.05).There was no significant difference in MYC protein expression among the other subgroups (P > 0.05).Conclusions: Our results show that ASA has a clinical value in the treatment of BC.ASA could overcome tamoxifen resistance in ER-positive BC cells through some key proteins, which may be potential therapeutic targets for patients with tamoxifen resistance.

Aspirin Regulation of C-Myc and Cyclind1 Proteins to Overcome Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells

Aspirin Disrupts the Mtor-Raptor Complex and Potentiates the Anti-Cancer Activities of Sorafenib Via Mtorc1 Inhibition.

Advances in mechanism of tamoxifen resistance in estrogen receptor-positive breast cancer

Aspirin Inhibits Cancer Metastasis and Angiogenesis Via Targeting Heparanase

Aspirin Attenuates YAP and Β-Catenin Expression by Promoting Β-Trcp to Overcome Docetaxel and Vinorelbine Resistance in Triple-Negative Breast Cancer.

Repositioning Aspirin to Treat Lung and Breast Cancers and Overcome Acquired Resistance to Targeted Therapy.

Aspirin Prevent Colorectal Cancer Via <i>enterococcus Cecorum</i> -TIGIT <sup>+</sup>treg Cell Axis

Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway

Aspirin enhances radio/chemo-therapy sensitivity in C. elegans by inducing germ cell apoptosis and suppresses RAS overactivated tumorigenesis via mtROS-mediated DNA damage and MAPK pathway

Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway.

AMPK-mediated Up-Regulation of Mtorc2 and MCL-1 Compromises the Anti-Cancer Effects of Aspirin

Role Of P38 Mapk In Enhanced Human Cancer Cells Killing By The Combination Of Aspirin And Abt-737

Aspirin inhibits tumor progression and enhances cisplatin sensitivity in epithelial ovarian cancer

Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-κB to the COX-2 promoter

Aspirin Regulates Gemcitabine Resistance in Pancreatic Cancer via Inhibiting the PI3K/Akt/mTOR Signaling Pathway and Reversing Epithelial-mesenchymal Transition

Aspirin and Metformin Exhibit Antitumor Activity in Murine Breast Cancer.

Research on Clinical Effectiveness of Aspirin for Treating Breast Cancer and Cell Protein Biomarkers on Aspirin Treatment in Drug-Resistant Estrogen Receptor-Positive Breast Cancer Cells

Aspirin Cooperates with P300 to Activate the Acetylation of H3K9 and Promote FasL-mediated Apoptosis of Cancer Stem-Like Cells in Colorectal Cancer

Aspirin inhibits prostaglandins to prevents colon tumor formation via down-regulating Wnt production

The Tgf-Beta Induced Gene, Pmepa1, Attenuates Antitumor Efficacy Of Aspirin In Triple-Negative Breast Cancer By Regulating Tgf-Beta 1

Enhanced Anti-tumor Efficacy of Aspirin Combined with Triptolide in Cervical Cancer Cells